259 results on '"Rocci, Alberto"'
Search Results
2. MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
3. RWD-derived response in multiple myeloma
4. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
5. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers
6. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
7. Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
8. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma
9. Assessment of Associations between Derived Response and Overall Survival in Patients with Multiple Myeloma Using a US-Based Electronic Health Records Database
10. Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial
11. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients
12. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
13. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
14. Lenalidomide for Multiple Myeloma
15. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations
16. Compound heterozygosity for two new TERT mutations in a patient with aplastic anemia
17. MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages
18. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
19. Analysis of Telomeres in Peripheral Blood Cells From Patients With Bone Marrow Failure1
20. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
21. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
22. Evaluating Suspected Cardiac Amyloidosis
23. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
24. Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations
25. Cancer-selective targeting of the NF-?B survival pathway with GADD45ß/MKK7 inhibitors
26. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
27. TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
28. High IKAROS Expression in Bone Marrow Environmental, But Not in Myeloma Cells Predicts for Survival with Lenalidomide-Dexamethasone Therapy in Myeloma
29. Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
30. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
31. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
32. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
33. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
34. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib
35. Cancer-Selective Targeting of the NF-kappa B Survival Pathway with GADD45 beta/MKK7 Inhibitors
36. RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
37. Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers
38. Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development
39. Lenalidomide for Multiple Myeloma
40. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
41. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
42. Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix
43. In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide
44. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
45. Abstract 4855: Proteomic characterization of the extracellular matrix in multiple myeloma
46. RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
47. The potential of miRNAs as biomarkers for multiple myeloma
48. Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients
49. Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors
50. Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.